GlassScriptPhysician profile
Arnold P Teo
NPI 1740429869
$4,387.00
in general payments reported to CMS, 2019-2025
41 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $230 · 2021: $480 · 2022: $1,129 · 2023: $927 · 2024: $360 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.88 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $487.12 | 2019-2022 | |
| Urovant Sciences INC | $321.08 | 2021-2022 | |
| Palette Life Sciences, INC. | $252.49 | 2021-2023 | |
| 180 Medical, INC. | $241.79 | 2020-2025 | Gentlecath, Gentlecath Glide, Cure Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $231.09 | 2020-2024 | |
| Dendreon Pharmaceuticals LLC | $208.84 | 2019-2024 | Provenge |
| Janssen Biotech, INC. | $200.84 | 2019-2025 | Erleada |
| Teleflex LLC | $189.64 | 2023 | Urolift |
| Endo Pharmaceuticals INC. | $188.83 | 2019-2023 | Edex, Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $181.98 | 2021-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $146.25 | 2022-2023 | Keytruda, Lynparza |
| Pfizer INC. | $141.52 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $137.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $120.41 | 2025 | |
| Antares Pharma, INC. | $119.20 | 2020-2025 | Xyosted |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $102.94 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $101.46 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $97.19 | 2023 | Orgovyx, Gemtesa |
| Medtronic, INC. | $82.30 | 2021-2025 | Altaviva |
| Olympus America INC. | $82.18 | 2023-2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $63.86 | 2024-2025 | Imfinzi, Lynparza |
| Halozyme INC | $61.59 | 2023 | |
| Boston Scientific Corporation | $60.84 | 2019-2023 | Spaceoar Vue System - 10ml |
| Endo USA, INC. | $52.66 | 2024-2025 | Xiaflex, Aveed |
| Immunitybio, INC. | $51.96 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $50.38 | 2022-2023 | Jynarque |
| Myovant Sciences INC. | $47.52 | 2021-2022 | |
| Coloplast Corp | $42.97 | 2019-2022 | |
| Tolmar, INC. | $32.96 | 2023-2025 | Eligard, Jatenzo |
| Neotract INC. | $31.42 | 2019 | |
| Telix Pharmaceuticals | $29.56 | 2023-2024 | Illuccix |
| Agiliti Surgical, INC. | $28.43 | 2023 | Trinity |
| Amgen INC. | $25.95 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $24.16 | 2021 | |
| Progenics Pharmaceuticals, INC. | $23.57 | 2023 | Pylarify |
| Accord Healthcare, INC. | $23.55 | 2022 | |
| Urogen Pharma, INC. | $21.92 | 2023 | Jelmyto |
| Medtronic USA, INC. | $21.70 | 2020 | |
| Axonics, INC. | $19.90 | 2023 | Axonics, Bulkamid |
| Blue Earth Diagnostics | $19.85 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.53 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Teo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.